Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene

Area of Science:

• Pulmonary Medicine
• Biomarker Discovery
• Inflammatory Diseases

Background:

• Matrix metalloprotease 9 (MMP-9) is implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, including inflammation and lung remodeling.
• Elevated MMP-9 may identify COPD patients with an inflammatory phenotype at higher risk for acute exacerbations (AECOPD).

Purpose of the Study:

• To investigate whether elevated circulating MMP-9 serves as a novel biomarker for identifying COPD individuals at increased risk of AECOPD.
• To assess the association of elevated MMP-9 with AECOPD frequency and severity in well-characterized COPD cohorts.

Main Methods:

• Analysis of data from the SPIROMICS and COPDGene cohorts, including baseline and prospective follow-up.
• Definition of elevated MMP-9 based on the 95th percentile of plasma values in non-COPD controls.
• Logistic, Poisson, and Kaplan-Meier analyses to evaluate associations with AECOPD.

Main Results:

• Elevated MMP-9 was found in 9% of SPIROMICS and 29% of COPDGene participants with COPD.
• COPD subjects with elevated MMP-9 showed a 13%-16% increased absolute risk for AECOPD.
• Elevated MMP-9 was independently associated with increased odds, frequency, and shorter time-to-first AECOPD in both cohorts.

Conclusions:

• Elevated MMP-9 is an independent prognostic biomarker for AECOPD risk in COPD patients.
• These findings highlight MMP-9 as a potential therapeutic target for managing COPD exacerbations.